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It is hypothesized that polymorphic light eruption is characterized by a partial failure of ultraviolet radiation-
induced immunosuppression, resulting in a delayed-type hypersensitivity response to photo-induced antigens. We
aimed to study the susceptibility of PLE patients to UVR-induced immunosuppression, by measuring the strength
of sensitization to 2,4-dinitrochlorobenzene after UVR exposure, and to diphenylcyclopropenone without UVR
exposure, in subjects with PLE and controls. Thirteen PLE patients and 11 controls were exposed to 1 minimum
erythema dose (MED) of UVR delivered from Waldmann UV-6 bulbs to the upper inner arm. Twenty-four hours later
at the same site they were exposed to a sensitizing dose of 2,4-dinitrochlorobenzene. One week later they were
exposed to a sensitizing dose of diphenylcyclopropenone at a nonirradiated site. Three weeks later all subjects
were challenged with four doses of 2,4-dinitrochlorobenzene and four doses of diphenylcyclopropenone. The
resulting increase in skin thickness was measured with Harpenden callipers and summed over the four doses, to
give a single value representing the reactivity of the subject to 2,4-dinitrochlorobenzene (RDN) and
diphenylcyclopropenone (RDP). Among all subjects, there was a very strong correlation between RDN and RDP
(Pearson correlation 0.56, p¼ 0.004). The strength of the reaction to 2,4-dinitrochlorobenzene relative to the
reaction to diphenylcyclopropenone was signiﬁcantly greater among PLE patients than controls (p¼ 0.04
independent samples t test of RDP–RDN). We conclude that induction of sensitization by 2,4-dinitrochlorobenzene
is suppressed less by UVR in patients with PLE than in healthy controls.
Key words: 2,4-dinitrochlorobenzene/diphenylcyclopropenone/immunosuppression/polymorphic light eruption/
ultraviolet radiation.
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In 1942 Epstein suggested that polymorphic light eruption
(PLE) might be due to a delayed-type hypersensitivity
response to autologous antigens generated by ultraviolet
radiation (UVR) (Epstein, 1942). It is hypothesized that the
production of these antigens occurs in all people, but that in
PLE there is a partial failure of UVR-induced immunosup-
pression, causing an abnormal response to these antigens.
We studied the susceptibility of PLE patients to UVR-
induced immunosuppression, by measuring the strength of
sensitization to 2,4-dinitrochlorobenzene (DNCB) after UVR
exposure, and to diphenylcyclopropenone (DPCP) without
UVR exposure, in subjects with PLE and nonphotosensitive
controls.
Results
The sex distribution, sun-reactive skin type, median MED,
and other characteristics of the two groups are shown in
Table I. UV irradiation did not induce PLE in any of the
subjects. The mean baseline skinfold thickness among the
controls was 1.96 mm (SD 0.49 mm); it was identical among
the PLE patients (SD 0.42 mm). The relationship between
dose of DNCB and increase in skinfold thickness in the two
groups is shown in Fig 1.
Among all subjects, there was a very strong correlation
between the strength of sensitization induced by DNCB
(SDN) and that induced by DPCP (SDP) (Pearson coefficient
0.56, p¼0.004, see Fig 2). The mean SDP, SDN, and SDP–
SDN values of each group are shown in Table II.
The immunosuppressive effect of UVR is reflected by the
difference between the response to DPCP (SDP) (sensitiza-
tion without UV exposure) and that to DNCB (SDN)
(sensitized after UV exposure). The difference in the values
of SDP–SDN between the control and PLE groups was
significant (p¼ 0.04, 95% CI of the difference 0.04, 3.00,
independent samples t test of SDP–SDN). There was no
association between skin type and the immunosuppressive
effect of UVR (skin type did not correlate with SDP–SDN;
Spearman’s rho coefficient 0.03, p¼ 0.87), nor was there an
association between baseline skinfold thickness and the
increase in thickness after application of the topical
sensitizers (baseline thickness did not correlate with
SDNþSDP; Pearson coefficient –0.271, p¼ 0.20).
Discussion
The eruption of PLE usually appears 2–24 h after sun
exposure. The condition is characterized by a dermal
Abbreviations: DNCB, 2,4-dinitrochlorobenzene; DPCP, diphenyl-
cyclopropenone; MED, minimum erythema dose; PLE, poly-
morphic light eruption.
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lymphocytic infiltrate that is dominated by CD4þ cells up to
72 h after UVR exposure, but later CD8þ T cells outnumber
those that are CD4þ (Norris et al, 1989). These features
suggest that PLE represents a delayed-type hypersensitivity
response to photo-induced antigens, as suggested by
Epstein (1942). There are at least two hypotheses to explain
how this might occur. First, it has been suggested that
in vitro epidermal cells from PLE patients, after exposure to
UVR, have an increased capacity to stimulate autologous
mononuclear cells, but that this is not the case with
epidermal cells of controls (Gonzalez-Amaro et al, 1991).
An alternative but not mutually exclusive hypothesis is that
PLE is characterized by a partial failure of UV-induced
immunosuppression, resulting in an abnormal response to
normal photo-induced antigens. We have investigated the
latter hypothesis.
In normal subjects the ability of contact allergens to
generate T cell mediated responses is reduced by UVR,
particularly UVB (Friedmann et al, 1989; Cooper et al, 1992).
This process involves the release of cytokines, particularly
tumor necrosis factor-a and interleukin-10, the appearance
of an HLA-DRþ /CD11bþ /CD1a– macrophage subset, and
the migration of Langerhans cells out of the epidermis
(Ullrich, 1995). It has been reported that Langerhans cells of
PLE patients are relatively resistant to this effect of UVR
(Kolgen et al, 1999); that study used super-physiologic
doses of UVB (6  MED), because lower doses do not
reliably induce the migration of Langerhans cells. Studying
sensitization to contact allergens after exposure to UVR
looks at the functional capacities of Langerhans cells, and
hence may be a more sensitive way of detecting differences
between PLE patients and controls, particularly when lower
(physiologic) doses of UVR are used. Furthermore, such a
study may be of more relevance to the pathophysiology of
PLE.
There is no structural similarity between DNCB and
DPCP, and cross-reactivity has been shown not to exist
(Kelly et al, 1998). There are two possible explanations for
the correlation between subjects’ reactivity to DNCB and to
DPCP. First, it has been shown that, although there is
variation between individuals in their overall reactivity, within
individuals there tends to be similar strengths of response to
different sensitizers (Moss et al, 1985). Secondly, particu-
larly given that the challenge doses were placed on the
same arm, it is possible that an intense immune reaction to
one antigen might result in a nonspecific upregulation of the
Table I. Characteristics of the two groups
Controls PLE
No. of subjects 11 13
Mean age (y) 46.0 39.1
Percentage male 36.4 23.1
Percentage atopica 36.4 23.1
No. of subjects with skin type
I 1 1
II 6 6
III 3 5
IV 1 1
MED (mJ per cm2): median 200 200
Range 130–290 130–420
aAtopy was defined as a personal history of asthma, hay fever, or
atopic eczema.
Figure 1
Increase in skinfold thickness in response to four doses of DNCB,
in PLE patients () and controls (*). Four weeks previously
volunteers had been sensitized to DNCB on skin irradiated 24 h
beforehand with 1 MED of UVR. Points are means, bars are SEM. The
difference in SDN values (which represent area under the curve)
between the control and PLE patients was not significant (p¼0.33,
95% CI of the difference 2.19, 0.76).
Figure2
Relationship of the response to DPCP and DNCB in PLE patients
() and controls (*). The best fit regression line is shown (r¼ 0.56,
p¼ 0.004).
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immune response to the other. Whichever explanation is
true, it does not affect our finding that the strength of the
reaction to DNCB relative to the reaction to DPCP was
significantly greater among PLE patients than controls.
One minimum erythema dose of solar-simulated radia-
tion given at the time of sensitization to DNCB suppresses
contact hypersensitivity by approximately 60% (Kelly et al,
2000). It seems very unlikely that without UVR exposure,
PLE patients would have a proportionally different reactivity
to DNCB relative to their reaction to DPCP, in comparison
with controls. Therefore, we conclude that in PLE patients
the reactions to DNCB were relatively strong compared with
those against DPCP, because PLE patients are immuno-
suppressed less than controls by exposure to 1 MED of
UVR.
Our subjects were not well matched for age, sex, or
atopic status. Subjects at extremes of old age (Friedmann,
1994), males (Rees et al, 1989), and atopics (Rees et al,
1990), tend to sensitize less well than younger subjects,
females, and nonatopics. This, however, does not affect our
main finding of a difference between SDP–SDN of controls
compared with PLE subjects, because SDP–SDN repre-
sents a within-subject comparison of the subject’s tendency
to become sensitized with, and without, UVR. The controls
are, if anything, less likely to sensitize strongly than the PLE
group; therefore, the controls’ SDP–SDN values might
deviate towards zero. In our system (in which most values
of SDP–SDN are greater than zero), this deviation would
appear as a failure to immunosuppress. Therefore, this lack
of matching does not weaken our finding that PLE subjects
immunosuppress less on UVR exposure than controls. The
11 irradiated controls were matched for skin type in the PLE
group; however, the latter had an additional two patients
who were both type III. It has been claimed that skin types
III/IV tend to immunosuppress less than types I/II on
exposure to 1 MED of solar-simulated radiation (Kelly et al,
2000), but other investigators have reported this is not the
case (Vermeer et al, 1991; Damian et al, 1997) and there
was no suggestion of any association in this study between
skin type and immunosuppression.
We have presented evidence that PLE is characterized
by a failure of UV-induced immunosuppression. In a PLE
patient exposed to the sun, this may result in an abnormal
response to normal photo-induced antigens. The difference
we have observed, however, may be one of many
differences in the cutaneous response to UVR between
PLE sufferers and normal people.
Materials and Methods
The study was approved by the Local Research Ethics Committee
and adhered to Declaration of Helsinki guidelines. Thirteen patients
with PLE and 11 healthy controls between the ages of 18 and 75 y
were recruited. All patients gave written informed consent to
participate in the experiments. The diagnosis of PLE was made on
clinical grounds. The morphologies of the PLE eruption were
papular (eight patients), papulovesicular (three), or vesicular (two).
Ten patients suffered from episodes of PLE in England; three
experienced attacks only when they were in sunnier climates.
Volunteers were excluded from the study if they were receiving
medication likely to affect immune function or sensitivity to UVR,
had a history of exposure to DNCB or DPCP or a history of skin
cancer, or were pregnant or lactating. All sensitization parts of the
study were conducted between September 2001 and May 2002;
there was no association between group and date of sensitization.
All procedures, including assessment of MED, sensitization to
contact allergens and elicitation reactions, were performed on the
skin of the upper inner arms.
Irradiation To establish the minimum erythema dose (MED), the
subjects received eight doses of UVR to areas each measuring 4
cm2. The UV irradiation source was a Waldmann 7001K machine
containing a bank of 20 Waldmann UV-6 bulbs with peak emission
at 320 nm, delivering 32% of output as UVB and 68% as UVA. The
test doses ranged from 100 to 500 mJ per cm2, increasing in
approximately 25% increments. The dose that caused just
perceptible erythema at 24 h was defined as the MED.
Sensitization to DNCB and DPCP DNCB and DPCP were
dissolved in acetone to the desired concentrations and applied
on paper discs 7.5 mm in diameter in 8 mm Finn chambers (Epitest
Oy, Finland). To induce sensitization 15.6 mg of DNCB was applied,
which gives a concentration of 35.4 mg per cm2, known to sensitize
nearly 100% of healthy individuals (Friedmann, 1994). This
sensitizing dose of DNCB was applied to the 1 MED site (located
on the upper part of one upper inner arm) at the time of reading the
MED, and left in place for 48 h. One week later 15.6 mg of DPCP
was applied to a nonirradiated site on the same upper inner arm,
and was removed after 48 h. The DPCP was not applied at the
same site as the DNCB; this was ensured by applying the former
on the lower part of the upper arm, observing the location of
hyperpigmentation from the MED series, and by patient and
investigator recall.
Challenge with DNCB and DPCP Three weeks later, baseline
skinfold thickness was measured on eight areas of the other upper
inner arm, using Harpenden callipers (John Bull, British Indicators
Ltd, St Albans, Herts, UK). To these areas, DNCB was applied in
8 mm Finn chambers at doses of 6.25, 8.75, 12.5, and 17.5 mg, and
DPCP at doses of 3.12, 4.37, 6.25, and 8.75 mg. These were
removed after 6 h, and 48 h after application skinfold thickness
was measured at each site. 0.1 mm was subtracted from the
results at the 12.5 and 17.5 mg doses of DNCB, because irritancy
studies in nonsensitized subjects showed that at these doses there
was an average increase in skinfold thickness of 0.1 mm (data not
shown).
The increase in skinfold thickness from baseline was calculated
for each dose, and is a measure of the degree of delayed-type
hypersensitivity to DNCB and DPCP. Using the same method as
Cooper et al, (1992), we summed the increase in skinfold thickness
over the four doses; this value is an approximation of the area
under the dose–response curve, and represents the reactivity of
the subject to DNCB (SDN) and DPCP (SDP).
Statistical analysis Correlations between continuous variables
were assessed by calculating Pearson’s correlation coefficient,
and between noncontinuous variables by calculating Spearman’s
rho correlation coefficient. In each subject SDN was subtracted
Table II. Mean RDN, RDP, and RDP–RDN in the two groups
(mm)
RDN RDP RDP–RDN
Controls 1.61 3.29 1.68
PLE 2.32 2.48 0.16
The difference in SDN values between the control and PLE groups was
not significant (p¼ 0.33, 95% CI of the difference –2.19, 0.76,
independent samples t test), nor was the difference in SDP values
(p¼ 0.39, 95% CI of the difference –1.09, 2.71). The difference in SDP–
SDN values was significant (p¼ 0.04, 95% CI of the difference 0.04,
3.00).
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from SDP to give a value representing the degree of immunosup-
pression induced by UVR. The values of SDP–SDN were compared
between PLE subjects and controls using independent samples t
test. All p-values were two-tailed and significance was assumed at
the 5% level.
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